
- 2025 SUD Sprint Cohort
- 2024 SUD Sprint Cohort
- 2023 SUD Sprint Cohort
2025 SUD Sprint Cohort
Welcome to our third SUD Sprint cohort. Learn about our members and connect!


Parker Reed Brewster »
Interval Therapeutics LLC
MORE …
Drug Delivery Implant Capable of Pulsatile Release
We are developing biodegradable, subdermal implants capable of delivering dozens of precisely timed drug pulses over extended periods without the need for electronics or patient interaction. The core innovation is a microfluidic “fuse” system that enables surface erosion-triggered, pulsatile release on a pre-programmed schedule. This technology offers strict dosing control, eliminates the risk of patient non-compliance, and prevents abuse or diversion—critical needs in the substance use disorder (SUD) landscape. By enabling consistent dosing without requiring frequent clinical visits, the device has the potential to improve therapeutic outcomes, support sustained recovery, and lower barriers to long-term SUD management.
Parker Brewster is the founder and CEO of Biomedical Think-Tank (BMTT), a venture studio that builds and de-risks early-stage medtech startups through student-led innovation. He has extensive experience in venture capital, having led diligence teams for the world’s largest angel investor network and collaborated closely with top-tier VC firms and accelerators. His work bridges research and commercialization, with a focus on translational medicine and strategic startup development. He is also an NIH translational science fellow and STTR grant recipient, currently advancing implantable drug delivery systems at Interval Therapeutics in his role as VP of R&D. His background spans fundraising, business development, and translational research, with a growing emphasis on regulatory strategy and scalable impact in underserved medical spaces.
I have extensive (given my youth) experience in fundraising, business development, and translational science, but little direct experience within the substance use disorder (SUD) landscape. Given the strong potential of our implantable technology to impact SUD treatment, I view this as a critical gap. I am participating in this program to better understand the unique clinical, regulatory, and commercialization challenges in the SUD field and to ensure that our development strategy aligns with the needs of patients, providers, and policymakers.

Alexander Colton »
Cosmos Pharmaceuticals Inc.
MORE …
Cosmos Device Enabled Medication Adherence Platform
Cosmos Pharmaceuticals has developed FortisKap, a biometric-enabled smart pill cap that tracks medication adherence in real time. Using fingerprint authentication, image-based pill counting, and secure data transmission, FortisKap helps patients stay on track with their prescriptions while providing healthcare providers with actionable insights to reduce readmissions, improve outcomes, and lower the cost of care.
Cosmos aims to offer a complete medication adherence solution that is enabled by FortisKap, a smart adherence device designed to secure and monitor adherence of patients in real time. Our platform tracks patient adherence of prescription regimens for specialty pharma, oncology, auto-immune, behavioral health and pain management patient populations. Cosmos distinguishes patient disease states for appropriate customer support, management and pricing. The patient-centric support and education tools enable each user to have a sense of control and influence over their treatment plan and well-being.
I want to participate in the Babson SUD Sprint to refine Cosmos’ business strategy, connect with fellow healthcare innovators, and learn how to scale our impact in addiction care and medication adherence. Cosmos was created in response to the devastation Substance Use Disorder can have—not just on individuals, but on their families and communities. Our mission is to reduce that burden and help patients get back to square one, faster and more effectively. This program is a unique opportunity to gain expert guidance, mentorship, and momentum toward our goal of reducing preventable overdoses and improving outcomes for those most at risk.

Lara Coughlin »
University of Michigan
MORE …
Incentives2Quit
Incentives2Quit (I2Q) is a hybrid human-digital smoking cessation intervention that combines personalized behavioral support with just-in-time incentive delivery. Grounded in contingency management and adaptive intervention principles, I2Q uses mobile technology to remotely verify abstinence and deliver monetary or non-monetary reinforcers based on real-time assessments of individual motivation, stress, and risk for relapse. Designed to integrate with public health systems and Medicaid delivery networks, I2Q aims to expand access to effective tobacco cessation support for underserved populations.
Lara Coughlin, PhD is a clinical psychologist and health services researcher whose work focuses on designing and implementing scalable interventions for tobacco and substance use, particularly among populations underserved by traditional healthcare systems. She is an Assistant Professor in the Department of Psychiatry at the University of Michigan and co-directs the Michigan Innovations in Addiction Care through Research and Education (MI-ACRE) program. Dr. Coughlin developed Incentives2Quit (I2Q), a hybrid human-digital intervention that leverages behavioral economics and mobile technology to deliver adaptive contingency management for smoking cessation. Grounded in just-in-time adaptive intervention (JITAI) principles, I2Q personalizes incentive delivery based on real-time assessments of motivation, stress, and risk for lapse. Her work bridges academic research, health system partnerships, and digital innovation to bring effective, equity-focused interventions into real-world care settings—including collaborations with Medicaid insurers and state health departments.
I’m excited to join the SUD Sprint because I’m passionate about making effective, evidence-based interventions more accessible to the people who need them most. As a clinical psychologist and researcher, I’ve seen firsthand the gap between what works in trials and what’s available in real-world care—especially for underserved communities. I developed Incentives2Quit to help bridge that gap, and I’m eager to learn how to take the next steps in translating this work into something sustainable, scalable, and impactful beyond academia.

Mikhail Giller »
Nudge Health Inc
MORE …
Nudge Adherence Device
The Nudge medication tracking device is built on a simple but effective concept: it detects whether your medication container has moved. If the container moves around the expected medication time, we assume the dose was taken. If it doesn't move, we can confidently identify that a dose was missed. Beyond this core functionality, Nudge includes visual and auditory alarms to help users remember to take their medication. If a dose is missed, an email alert is sent to the user—and, importantly, to their caregiver as well. This real-time adherence reporting enables timely interventions by care providers, helping to drive better health outcomes. Nudge also includes features like cellular connectivity, pre-activation, and a user-friendly design—making it accessible even to those without smartphones or Wi-Fi. Our current focus is ensuring Nudge serves as a powerful tool when used alongside intervention programs, where it can have the greatest impact.
Mike Giller, founder and CEO of Nudge Health, brings a strong background in technology and leadership. With a degree in computer science, I began my career as a developer, then moved into client-facing consulting roles, transitioned into technical sales, and eventually took on responsibility for product strategy and roadmap development. This diverse experience has prepared me to wear the many hats required on the unpredictable path of entrepreneurship. My entrepreneurial journey began with a desire to make a positive impact. Managing medications for my kids, pets, parents—and eventually myself—highlighted a clear need: a simpler way to stay on top of medications without the complexity of traditional mobile apps. That’s when the idea for Nudge was born. The technical challenge was straightforward, so I dove in. After just over a year of development, Nudge came to life. Now that the product is ready, I’m focused on finding the best market fit. One area I’m especially passionate about is addiction treatment. Given how critical medication adherence is in that space, I’m excited about the potential for Nudge to help people stay on track—and ultimately beat their addiction.
I want to participate in this course because I believe Nudge can make a real difference in the fight against Substance Use Disorder (SUD). Medication adherence is often a critical part of recovery, especially with treatments like buprenorphine or naltrexone, where missed doses can lead to relapse. Nudge helps by passively tracking whether a dose was likely taken—no apps, buttons, or data entry required. If a dose is missed, both the individual and their caregiver or provider are alerted in real time, creating an opportunity for timely intervention. For example, if someone struggling with opioid use disorder forgets their morning dose, Nudge can alert their support system before the window for effective treatment closes. Or in a residential program, staff can use Nudge to monitor multiple clients without invasive check-ins, allowing them to focus their attention where it's most needed. I’m excited to collaborate with others in this course to refine how Nudge fits into SUD programs and to learn how we can maximize its impact.

Adela Grando »
Arizona State University
MORE …
Substance Use Health Record Sharing Technology
We have created a novel, standard-based technology to allow patients to control the sharing of their sensitive (e.g. substance use disorder information) medical records. Supported by SAMHSA, ONC and NIDA, this technology builds on the latest data interoperability standards (e.g. FHIR) and it is EHR-vendor agnostic.
Adela Grando, PhD, MCS, FAMIA, FACMI is an Associate Professor in Biomedical Informatics and teaches students in graduate coursework. She serves as faculty at Arizona State University’s Barrett, the Honors College. Additionally, she is an Adjunct Assistant Professor at the Mayo Clinic. Previosly, she was faculty for the HonorHealth Clinical Informatics Fellowship. She has trained in US, Europe and Latin America in computer science and biomedial informatics, including the University of California, San Diego, Oxford University and the University of Edinburgh. Her areas of expertise are Healthcare Information Technology (HIT), Patient-centered Technology and Mobile Health. She has been nationally recognized for her significant contributions to clinical informatics, being inducted as Fellow of the American Medical Informatics Association (FAMIA) and Fellow of the American College of Medical Informatics (FACMI).
I want to transform this academic project into production. I am looking for ways to bring this technology to healthcare.

Lipin Ji »
MAKScientific, LLC.
MORE …
CB1 neutral antagonist for AUD and other SUDs
Our novel drug candidate has strong preclinical validation, targeting a clinically proven mechanism for alcohol use disorder. Previous efforts were hindered by unwanted psychiatric/GI side effects, but our novel pharmacology showed great efficacy without such side effects. With multiple patents secured (composition of matter, process chemistry, and formulation), it is currently in IND-enabling studies and on track for an IND filing this summer.
Lipin Ji earned his Ph.D. degree in medicinal chemistry at Northeastern University in 2021, mentored by Dr. Alexandros Makriyannis. During his study in the Center for Drug Discovery at Northeastern University, his main research focuses on the medicinal chemistry and drug design of small molecule medication targeting the endocannabinoid system. His current research is on the development of CB1 neutral antagonist for the treatment of alcohol use disorder and other substance use disorders.
The SPRINT program will help refine our strategy, strengthen investor discussions, and navigate the regulatory and commercial pathways to bring our candidate to market.

Matthew Lally »
LallyMD.com
MORE …
Web-Based Animation App for Medications to Treat Substance Use
Design, code, and publish a web-based animated reference that covers all FDA-approved medications that treat substance use disorders. The design and animation will make it a resource for both clinicians and non-clinicians.
I am a board-certified in Psychiatry and Addiction Medicine. I graduated from the University of Massachusetts Medical School. I completed General Psychiatry and Child/Adolescent Psychiatry training at the University of Arizona. I am board-certified in Addiction Medicine and I have been treating patients with substance use issues for 20 years. Through my company, LallyMD.com, I design, code, and publish animated mental health apps used by clinicians across the globe. These apps are designed to transform lengthy, text-based medical reference information (which is often unread) into appealing, color-coded, easy-to-use animation with the goal of improving patient safety.
I use design, coding, and animation to create references to improve patient care and safety. This course will enable to maximize the reach of an animated app to help those struggling with substance use.

Yasmin Escobedo Lozoya »
AntoZero LLC
MORE …
NeuroStat-Addiction: A Precision Platform for Anti-Relapse Therapeutics
AntoZero is developing NeuroStat-Addiction, a groundbreaking in vitro platform targeting the brain plasticity mechanisms that drive addiction relapse, a major failure point in current SUD treatments. High relapse rates stem from persistent maladaptive changes in brain circuits, particularly involving Medium Spiny Neurons (MSNs). We use patient-derived cells reprogrammed into functional MSN circuits and employ HT functional imaging to quantify network instability and maladaptive plasticity. This function-first human platform enables the discovery and validation of novel anti-relapse therapeutics by directly assessing their ability to restore healthy network dynamics, offering a precision approach to break the cycle of chronic SUDs.
We need access to the critical resources provided by the fellowship to transform our scientific insight into a scalable, impactful solution. We expect the fellowship's focus on addressing uncertainty in commercialization will serve us well. By combining scientific insight with entrepreneurial strategy, we can develop interventions that are not just scientifically innovative, but can be translated into scale that will truly be transformative.

Muhammad Adeel Parvaz »
Icahn School of Medicine at Mount Sinai
MORE …
Participant Recruitment and Retention Platform for SUD Research and Clinical Trials
An online platform designed for academic research institutions and industry investigators to recruit, retain, and interact with potential research participants for SUD-related research studies and clinical trials.
I am an Associate Professor in the departments of Psychiatry, Neuroscience, and Artificial Intelligence & Human Health at the Icahn School of Medicine at Mount Sinai, in New York City. My primary research interest includes studying cognitive-affective interactions underlying deficits in motivation, reinforcement learning and inhibitory control in neuropsychiatric conditions, using behavioral, computational, psychophysiological and neuroimaging techniques. As a cognitive neuroscientist with a background in biomedical engineering, I place special emphasis on understanding disease mechanisms with an eye towards developing and validating clinically useful biomarkers to accelerate bench-to-bedside translation of lab-based assessments. Currently, my research involves tracking neurobehavioral plasticity during the onset of as well as remission from substance use disorders. At the clinical translation side of this work, our group is developing an assay to test different pharmacological, cognitive/behavioral and neuromodulation interventions for craving reduction in substance use disorders. In parallel, I am interested in studying the onset and development of aberrant cognitive-affective interaction in adolescents as well as risk factors that render some youth vulnerable to develop psychopathological phenotypes (e.g., substance use disorder, eating disorders and psychosis). For these studies, we use a comprehensive multimodal approach with multiscale modeling of exposomic (environmental, non-genetic factors), clinical (interviews and questionnaires), behavioral (cognitive tasks, speech, facial expressions), molecular (MR spectroscopy and blood based inflammatory markers), psychophysiological (EEG) and circuit-level (fMRI) biomarkers to precisely define the phenotype of interest and to track or predict clinical outcomes (e.g., development of substance use in adolescents and relapse in treatment seeking addicted individuals).
I would like to participate in this course to gain a better understanding on how to get opinions from key stakeholders, and develop, scale, and commercialize this platform.

Tiffany Pleasant »
Brighton Center
MORE …
Promoting Financial Management Skills in Individuals Recovering from Substance Use Disorders
In recovery, a lot of talk centers on emotions, spirituality, and self-awareness. One thing that likely isn't discussed enough is money management even though it might be one of the most important keys to a successful recovery.
Many people dealing with addiction use up their entire life savings to fund their addiction. As soon as they receive cash, they spend it on their substance of choice until they find their way into homelessness, poverty, and debt. Even those who don't find themselves in financial ruin begin to associate spending money with the rush of getting high. This can turn money into a powerful trigger or lead to spending on other things becoming a replacement addiction. For these reasons, money management is just as important as the "Big Three"—people, places, and things to avoid—and it is critical to understand this fourth threat to sobriety. Financial management is a life skill that many in recovery may not have learned or may have lost over the course of their active addiction.
While poor money management may not seem connected to being able to spend money on drugs and alcohol, it is directly tied to substance abuse. Poor money management leads to debt, and debt leads to stress. When a person begins to feel hopeless and unable to change their situation, they may turn to drugs or alcohol to cope. This is no different than the loss of hope that could come with struggling to find employment or having trouble paying bills. Like other relapse triggers, the key to avoiding relapse is to understand the trigger and learn how to avoid it. Recovery centers can start to teach and reinforce lifelong money management techniques like budgeting, tracking spending, having a bank account, and saving money. This education is key to steering people who are early in recovery down the right path.
In November 2022, I attained certification as a HUD Certified Housing Counselor. Since that time, I have supported clients in their financial endeavors, which includes assisting with budgeting, providing financial education, setting and planning goals, enhancing assets such as homeownership, and improving credit scores. Throughout this journey, I have had the privilege of working with individuals recovering from Substance Use Disorders (SUDs), and I have recognized a significant demand for these services to facilitate their success. Currently, I hold the position of Financial Wellness Coordinator for a team of HUD Certified Housing Counselors, where I guide and support our team in helping clients achieve their financial objectives. Additionally, I am pursuing a Bachelor’s degree in Psychology, with an expected graduation date of May 2028.
This course will provide the necessary education to establish a platform for financial education and counseling that can be disseminated. It will facilitate the application process for grant assistance and data collection, while also promoting connections and building a supportive network to achieve the objective.

Bradley Ray »
RTI International
MORE …
FORTRESS (Fatal Overdose Review Teams – Research to Enhance Surveillance Systems)
Indiana state government collaborated with external research partners to facilitate an innovative real-time dashboard by integrating administrative data sources through record linkage, enabling timely identification of overdose “touchpoints” across medical and criminal-legal systems. This collaboration leveraged state data infrastructure and analytic expertise to produce actionable insights for county-level overdose fatality review teams. The dashboard supports data-driven decisions by illuminating where interventions can be targeted to prevent overdose deaths.
Brad Ray, Ph.D., is a Senior Researcher at RTI International specializing in public health, harm reduction, and criminal-legal system reform. He has authored over 100 peer-reviewed publications focused on overdose prevention, drug policy, and innovative interventions to reduce drug-related harm. Dr. Ray leads research to strengthen data-driven decision making, including work on the FORTRESS project which enhances statewide overdose surveillance systems that can inform county-level evidence-based overdose prevention strategies.
I am interested in attending the Babson SUD Sprint to explore how the FORTRESS dashboard, developed in collaboration with Indiana’s state agencies, can be expanded to other states through a sustainable, commercially viable model. My hope is that the focus on entrepreneurship, stakeholder mapping, and financing strategies will equip me with information to translate this innovative public health data system into a scalable product that supports data-driven overdose prevention nationwide. By connecting with mentors and investors in this space I hope to build partnerships that can accelerate the adoption and impact of FORTRESS beyond Indiana.

Tom Rust »
Veterans Affairs
MORE …
Remote Methadone Titration
Strong, synthetic opioids (like fentanyl) are killing more people with opioid use disorder (OUD) than ever. Methadone is more effective for patients with higher tolerance, but not enough people start or stay in treatment, as methadone clinics are scarce, and patients must visit the clinic daily for at least the 6–8-week titration period and usually much longer. We propose a novel approach to treating OUD with methadone via telehealth, alleviating the need for daily visits and expanding the geographic coverage of existing clinics. Home-based treatment requires three components—secure at-home storage, observed dosing, and responsive dose adjustment—all of which have been developed and are commercially available separately. Combining these elements will allow patients to start taking methadone at home on Day 2 of treatment, similar to most other medications for chronic conditions.
Tom Rust is a systems scientist at the VA’s Office of Healthcare Transformation, where he builds problem-solving teams, mediates conflict across silos, and searches for high leverage changes to improve healthcare delivery. An expert in lean quality improvement and simulation modeling, he uses participatory methods to help groups untangle interdependencies in healthcare processes, predict the full consequences of policy decisions, and build the VA’s capacity for systems thinking. With over a decade of experience in healthcare, he has led projects that have measurably improved patient outcomes, reduced wait times, and saved millions of dollars. Tom holds a PhD in System Dynamics from Worcester Polytechnic Institute, has taught operations management and systems thinking courses at the Boston University School of Public Health, and helped found the VA’s first Patient Safety and Quality Improvement medical resident rotation. He hails from Nevada and lives in Boston with his wife and two young, precocious children.
I need this program to help turn what is currently a “VA SUD innovation dissemination” project into a self-supported (i.e., revenue-generating) venture that can thrive in the private market. We need to become entrepreneurs if we’re ever going to get our solution to the vast majority of patients still in “liquid handcuffs.”

Martine Senatus »
VIP Integrative Health Care LLC/ Pathways To Wellness Foundation Inc.
MORE …
Light Therapy for OUD
Light therapy is a way to help treat substance use disorders by using certain types of light to affect the brain in a way that can lower cravings and ease withdrawal symptoms.
Dr. Martine Senatus PMHNP-BC FNP-BC is a board certified family and psychiatric mental health nurse practitioner. She owns a multispecialty psychiatric mental health and primary care group practice and Pathways To Wellness Foundation, Inc a non profit health care clinic in Palm Beach County. Pathways To Wellness Foundation, Inc has recently been contracted by the state of Florida Department of Children & Families to provide mobile outpatient medication assisted treatment services for rural and homeless patients with opioid use disorder. Her passion is to help people. She has served in the Ministry as lead worship leader, Children's ministry assistant director for over 12 years, and uses this passion to serve our community. She believes all person should have access to care and a home to live. Her goal is to provide evidenced-based, compassionate, quality and safe care for all persons.
I would like to participate in Babson College’s SUD program to accentuate and develop my understanding of innovative, entrepreneurial approaches to addressing addiction. This opportunity will help me develop practical strategies and entrepreneurial skills to create impactful, solutions for those affected by SUDs.

Ingrid Serck-Hanssen »
Alpha Element Institute LLC
MORE …
Kala.coach - an online self-directed SUD prevention intervention and learning platform
Kala.coach is an online self-directed SUD prevention intervention and learning platform for women based on a novel conceptual framework of four Vitality Type patterns in behavior and cognition. Vitality Type patterns are applied as assets-based cognitive tools to explore terminology to gain new self-awareness and personalize self-regulation strategies.
My training, expertise and leadership experience have prepared me to successfully carry out the proposed research and prototype development of Kala.coach. My passion and commitment are to develop accessible, scalable interactive digital therapeutics to help empower women with SUD to self-regulate and manage stress and negative affect. With a background that includes mental health counseling, business administration, organizational development as well as sales and marketing, I have served as a business leader and team member on a wide range of projects through successful completion. This includes the hiring and management of staff, budget development and oversight, intellectual property protection and business operations as well as co-authoring publications and presenting research at conferences.
I am excited to participate in this course to learn entrepreneurial leadership skills. As a practicing mental health clinician and co-founder of Alpha Element Institute, I have passion and background for successfully participating in this program in order to bring Kala.coach to market as a women-focused SUD prevention intervention.

Marit Solheim-Witt »
Alpha Element Institute LLC
MORE …
Empower-rx
Empower-rx is a virtual reality immersive and therapeutic learning platform to reduce and control cravings for substances. Empower-rx is an interactive and positive learning experience that is self-paced and personalized along the way. It is distinguished from other digital therapeutic platforms and devices through the application of Alpha Element Institute’s model of Vitality Type patterns in behavior and cognition, color-matrix instrument and related IP. Empower-rx includes real-time feedback and adjustment features to ensure the virtual reality experience is tailored to individuals’ current needs—tracking progress and empowering them to gain skills and confidence to take control of their recovery journey.
I am the founder of Alpha Element Institute where I conduct research on Alpha Element theory and conceptual framework of human development. The Alpha Element® model is a theoretical, semantic model of four Vitality Type patterns as proposed schema in behavior and cognition on four levels of awareness: instinct, emotion, intellect, and insight. My current focus is on research and application of the Alpha Element model to the development of intelligent technology to empower individuals struggling with recovery from substance use disorders. I am the author of Alpha Element Institute’s interactive assessments (Vitality Type™ indicators) and co-author of related books and instructional materials. With a special interest in the stressful work environment of today’s healthcare professionals, I develop and teach continuing education courses for mental health professionals on the application of the Alpha Element model to interprofessional education, interpersonal communication and behavioral health. I am a holistic health coach and previously worked as an instructor at the Center for Integrative Health, Bloomington, MN. Prior to my career in holistic health, I was a program manager at Jack Morton Company, an experiential marketing agency, and a writer and consultant. I was born in Norway, raised in Belgium and Germany and graduated from the University of Minnesota with a double-major in American Studies and Studio Arts. I have a Masters in Holistic Health Studies from St. Catherine University, St. Paul, Minnesota.
There is an urgent need for innovative tools to empower individuals with SUD to overcome their cravings. We have an innovative framework perfectly positioned to leverage the latest developments in optical devices, psychiatry and neuroscience research. However, I am personally in need of skills, tools and support to develop the entrepreneurial leadership capacity to accomplish our goal to become the leading provider of VR-based optical technology in SUD recovery. The SUD Sprint at Babson was recommended to me by a colleague and after attending an informational webinar I am very excited about the opportunity to attend this training because the path ahead is daunting and I seek mentors, peers and knowledge to tackle and rise to the challenges and opportunities ahead.

Dawn E. Sugarman »
McLean Hospital
MORE …
Digital Intervention for Women with Substance Use Disorders
My innovative solution is a digital intervention for women with substance use disorders (SUDs) to provide psychoeducation, personalized feedback, and coping skills training. This digital intervention gives women the tools they need to make changes to their substance use, manage their co-occurring mental health symptoms, and empower them to learn about sex-specific implications of their substance use on their health and well-being.
Dawn E. Sugarman, PhD, is a research psychologist in the Division of Alcohol, Drugs, and Addiction at McLean Hospital and an Assistant Professor in the Department of Psychiatry at Harvard Medical School. She is the Director of McLean Hospital’s Clinical Measurement Initiative, focused on electronic collection of patient-reported outcomes to inform individual routine patient care and assist in program outcomes assessment. Dr. Sugarman focuses her research and clinical work on the treatment of addictive behaviors. She is particularly interested in treatment for women with substance use disorders and the use of technology in effective treatment dissemination. Dr. Sugarman was the inaugural recipient of the Sarles Young Investigator Award for Research on Women and Addiction. She is a current recipient of a National Institute on Drug Abuse (NIDA)-funded career development award focused on increasing women’s engagement in medication treatment for opioid use disorder through digital intervention. Dr. Sugarman also serves as the Managing Editor for the Harvard Review of Psychiatry.
My goal in participating in the SUD Sprint program is to learn the skills necessary to develop a commercialization plan and business strategy to scale my solution for women with SUD. In addition, I would like to better understand how to collaborate with industry partners and communicate with potential investors.

Elissa Weitzman »
Boston Children’s Hospital, Harvard Medical School
MORE …
Developing the “Take Good Care” Intervention for Broad Commercial Dissemination
The “Take Good Care” innovation is an evidence-based, brief, scalable, electronic preventiver intervention addressing substance use risks for adolescents with chronic medical conditions.
Dr. Elissa Weitzman, ScD, MSc, is an internationally recognized social and behavioral scientist who has made significant contributions to understanding and ameliorating problems related to adolescent substance use and chronic illness. She is an Associate Professor of Pediatrics at Harvard Medical School, Director of Research for the Division of Addiction Medicine (DADM) at Boston Children’s Hospital where is also Associate Scientist in the Division of Adolescent/Young Adult Medicine, faculty in the Computational Health Informatics Program (CHIP) and the Population and Development Studies Center at the Harvard T.H. Chan School of Public Health. Drawing from epidemiology, medical sociology, public health in psychiatry, informatics, and ethics, she has authored more than 150 scientific papers, numerous book chapters, and opened new areas of research about substance use among medically vulnerable youth, the intersection of pain, medical opioid exposure, and risk for opioid use disorder and overdose, and acceptability of novel vaccine technologies to protect against overdose. Her research extends to pioneering the integration of digital health tools and platforms into health surveillance, evaluation of quality and safety of these tools, understanding acceptability to patients and citizens of digital and computational approaches to advancing health research and risk assessment, and willingness to engage in precision prevention efforts that involve returning individual and aggregate research results about genotypic and phenotypic risks for substance use disorder. She leads the quality improvement program for the DADM, where she is innovating approaches for ensuring attention to the “whole child”.
Currently, there are no broadly available preventive interventions addressing the unique risks of medically vulnerable youth. In the U.S., 1-of-4 teens is growing up with a chronic medical condition. These youth are at higher than average risk of developing substance use disorders. The primary goal of participating in this course is to do develop a plan and relevant skills for advancing commercial development of a novel innovation that can address a major gap in substance use prevention.

Bing Xie »
Biagon Inc.
MORE …
Biophysics‑Driven ML Prediction of GPCR Signaling Efficacy
We leverage AI-powered in-silico methods to design safer analgesics, combining machine learning and biophysics to tackle the complexity of GPCR signaling pathways, which are linked to the side effects of opioids and cannabis, including addiction. This fully computational approach is faster, more cost-effective, and efficient, accelerating the discovery of safer, more effective treatments for substance use disorders.
I am a Senior Scientist at Biagon Inc. I use AI and computer-based methods to predict how well drugs will work and to design new ones. At Biagon, I integrate machine learning, chemistry, and molecular modeling to support better decision-making in drug discovery. My past experiences in research and software development prepared me for this work. I first became interested in computational chemistry during my Ph.D. at the Illinois Institute of Technology. There, I developed methods to estimate the binding free energy between small molecules and proteins. I focused on making these calculations faster and more accurate. After my Ph.D., I wanted to use my methods for real-world problems. I joined the National Institute on Drug Abuse (NIDA/NIH) as a postdoctoral fellow. I studied how synthetic opioids such as fentanyl and its analogs, bind to the mu-opioid receptor. My goal was to help design safer analgesics. I also researched dopamine receptors to understand how certain compounds affect their activity. Later, I decided to build tools for broader use. I moved to OpenEye, Cadence Molecular Sciences as a Scientific Software Developer. There, I learned industry programming skills and led projects to improve drug discovery software. I developed algorithms for simulating molecules and methods to study water interactions in proteins. These tools made simulations faster and more reliable for cloud-based platforms. Now at Biagon Inc., I combine my chemistry knowledge, research experience, and software skills to create AI-driven tools for drug discovery. Each step in my career—from Ph.D. to postdoc, then to industry—helped me grow. I changed roles to apply my skills in new ways, solve bigger problems, and turn scientific ideas into practical tools.
This program offers a unique opportunity to grow as an entrepreneur and expand my expertise beyond science. My work in SUD has driven my passion for developing safer analgesics. During my postdoc and time as a research fellow at National Institute on Drug Abuse (NIDA), I saw the severe impact of drug abuse firsthand. My goal was to create safer analgesics. This experience strengthened my commitment to finding solutions for SUD. Now, in a startup, I'm focused on predicting compounds that could offer safer alternatives for pain relief. This program will help me refine the entrepreneurial skills needed to translate this scientific knowledge into impactful, scalable solutions.

Qingguo Xu »
Virginia Commonwealth University
MORE …
Nor-LAAM depot for treating OUD
Current FDA-approved medications for the treatment of opioid use disorder (OUD), methadone, buprenorphine, and naltrexone, have demonstrated efficacy in mitigating opioid cravings, alleviating withdrawal symptoms, and blocking euphoric effects. However, some challenges still exist, including poor patient retention, increased risk of overdose, low efficacy, and undesired side effects. The nor-Levo-α-acetylmethadol (nor-LAAM) is an active metabolite Levo-α-acetylmethadol (LAAM), with even higher potency and better safety than LAAM. We are developing a new depot formulation of nor-LAAM (nor-LAAM-MP) lasting at least 1 month to provide a novel safe and effective medication to treat opioid-dependent OUD patients (PCT/US2023/012247, Feb 3, 2023).
Our pilot data have already demonstrated that nor-LAAM-MP successfully reduced fentanyl choice and shifted preference to food on the fentanyl-dependent rat model (Journal of Controlled Release 373 (2024) 93–104). Furthermore, nor-LAAM-MP attenuated fentanyl somatic withdrawal symptoms in the fentanyl-dependent rats. The sustained release of nor-LAAM-MP holds great potential as a new OUD therapy with improved therapeutic efficacy and enhanced patient compliance.
Qingguo Xu, D.Phil., is a Blick Scholar Associate Professor of Pharmaceutics, and Pharmaceutical Engineering, with joint appointment in Biomedical Engineering, Ophthalmology, Pediatrics and Massey Cancer Center at the Virginia Commonwealth University. Dr. Xu received B.E and M.E. in Polymer Materials from Tianjin University in China, and D.Phil. in Materials Science from the University of Oxford, and received postdoc training from Johns Hopkins School of Medicine. Dr. Xu has a broad background in materials science, drug delivery, nanotechnology, and physiochemical characterization of mucosal and tissue barriers to drug delivery systems. A significant portion of his current work has involved the design and development of new methods for safe, effective drug delivery to treat various diseases, including opioid use disorders. He is an inventor on over 15 patents and patent applications, among which three have been licensed to companies and successfully commercialized. He runs an active research program with multiple NIH and FDA grants, including an NIDA UG3.
I plan to spin out a company aiming to develop a depot formulation of nor-LAAM for treating OUD.